Drug Farm to Present Ophthalmologic and CNS Findings from Phase 1b Study of First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at ARVO 2026

ALBANY, N.Y. & SHANGHAI--(BUSINESS WIRE)--Drug Farm today announced ophthalmologic and central nervous system (CNS) findings from its Phase 1b study of DF-003, a first-in-class oral ALPK1 inhibitor, will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2026 annual meeting in Denver, CO. The presentation will highlight early evidence of improvements in visual function, optic nerve pathology, and neurological symptoms in patients with ROSAH syndrome, a rare genetic